Alnylam Pharmaceuticals, Inc. logo ALNY - Alnylam Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 39
HOLD 12
SELL 1
STRONG
SELL 0
| PRICE TARGET: $445.67 DETAILS
HIGH: $530.00
LOW: $351.00
MEDIAN: $445.50
CONSENSUS: $445.67
UPSIDE: 49.83%

Stock News

Alnylam Issues 2025 Corporate Responsibility Report

Alnylam Issues 2025 Corporate Responsibility Report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, “Accepting Challenges to Improve the Health of Humanity,” which remains central to Alnylam's strategy and is embedded across.

May 19, 2026 04:30 AM • businesswire.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the Dow Jones Industrial Average, which closed 0.32% higher at 49,668, finished the day lower. The small-cap Russell 2000 was the big loser... Here Are Tuesday's Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

May 19, 2026 04:04 AM • 247wallst.com
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and.

May 11, 2026 10:30 PM • businesswire.com
Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam to Webcast Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida. A live audio webcast of each presentation will be.

May 07, 2026 04:00 AM • businesswire.com
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients.

May 04, 2026 04:30 AM • businesswire.com
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year

Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year

Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise growth despite insurance and pricing headwinds; Amvuttra continues to gain front-line share. ALNY maintains full-year TTR revenue guidance of $4.4B–$4.7B, with ongoing investments in earlier diagnosis and care coordination to expand the addressable market.

May 01, 2026 08:25 AM • seekingalpha.com
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2026, and reviewed recent business highlights. “2026 is off to a strong start for Alnylam with the end of the first quarter marking one year since the U.S. launch of AMVUTTRA for ATTR-CM, and also representing a significant financial milestone with the achievement of over $1 billion in quar.

Apr 30, 2026 04:00 AM • businesswire.com
Brown Advisory Large-Cap Growth Strategy Q1 2026 Portfolio Review

Brown Advisory Large-Cap Growth Strategy Q1 2026 Portfolio Review

Netflix outperformed during the period as investor concerns around a potential acquisition of Warner Bros. Discovery subsided. Microsoft lagged during the quarter despite reporting strong underlying results, as investor focus remained on slightly softer Azure growth and elevated AI-related investment. We believe Alnylam Pharmaceuticals' differentiated platform and growing pipeline position it well for sustained long-term growth.

Apr 17, 2026 02:45 AM • seekingalpha.com
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2026 results as well as expectations for the future via conference call on Thursday, April 30, 2026 at 8:30 am ET. A live audio webcast o.

Apr 16, 2026 04:00 AM • businesswire.com
Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Massachusetts Financial Services Co. MA Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Massachusetts Financial Services Co. MA lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 38.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 495,307 shares of the biopharmaceutical company's stock after acquiring an additional 138,778 shares during the quarter.

Apr 13, 2026 01:28 AM • defenseworld.net

Price Targets